Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrated Meaningful Responses with Tovorafenib (DAY101) in Pediatric Low-Grade Glioma
“The responses we’ve observed in the FIREFLY-1 study with weekly monotherapy tovorafenib in children with recurrent or progressive low-grade gliomas are very encouraging,” said Samuel Blackman, M.D., Ph.D., co-founder and chief medical officer of Day One. “As tovorafenib progresses in the clinic, we want to thank the patients, their families, the clinical investigators, and the advocates who have chosen to participate in the FIREFLY-1 clinical trial and support the development of a potential new treatment for children in need of new therapeutic options.”
Share:
More News
OriCell co-founder, Chairman and Chief Executive Officer Dr. Yang Huanfeng commented: “We are deeply grateful to the NMPA Centre for Drug Evaluation and relevant government authorities for their strong support of innovative drug development, and to Academician Fan, Professor Qin and their teams for their trust and active participation. This
Louise Modis, Chief Executive Officer at Amphista, said: “FDA clearance of our IND for AMX-883, our lead Targeted Glue™, for acute myeloid leukaemia is a significant milestone as we transition into a clinical-stage company. AMX-883 is the only BRD9 degrader currently being developed and the compelling preclinical findings submitted to
“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The FDA’s filing acceptance brings us closer to delivering a new standard-of-care with the
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment